Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Old polio vaccine may offer new shield against COVID-19

NCT ID NCT04445428

Disease control Sponsor: Bandim Health Project Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving the oral polio vaccine (OPV) to adults over 50 in Guinea-Bissau could reduce their risk of getting sick or dying from COVID-19 and other infections. Researchers enrolled about 3,700 people and gave half the vaccine plus COVID-19 advice, while the other half got advice only. The idea is that live vaccines like OPV can boost the immune system broadly, not just against polio.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oral polio vaccine (OPV)
What this could lead to
If it works, this could point toward a cheap, widely available vaccine that offers some protection against COVID-19 and other infections.
What could go wrong
This is a completed Phase 4 trial in one African country, so results may not apply elsewhere. OPV is not a specific COVID-19 vaccine and may not provide strong or lasting protection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

3,729 people

The number who actually took part.

Started

Jul 2020

Finished

Jun 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Living in a household which has had a census visit conducted after 1 January in 2017. Age above 50. Exclusion Criteria: * Previous adverse events to OPV; Previous documented COVID-19; Acute severe infection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID Morbidity Mortality Non-specific effects of vaccines Poliovirus vaccine, oral

Contacts and locations

Locations

  • Bandim Health Project

    Bissau, Guinea-Bissau

More trials for these conditions

Other studies related to the condition(s) this trial covers.